Stay updated on ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial

Sign up to get notified when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The page now displays the completed Phase 1 study record for enfortumab vedotin, with details on the trial’s purpose, treatment plan, eligibility, outcomes, and participating locations, rather than a forbidden-access error.
    Difference
    69%
    Check dated 2026-11-09T13:58:09.000Z thumbnail image
  3. Check
    18 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov footer revision changes from v3.7.2 to v3.8.0, while the page continues to show a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-02T15:54:00.000Z thumbnail image
  4. Check
    25 days ago
    Change Detected
    Summary
    A site-wide banner announces an NIH transition notice about using “Super Intelligence” in place of “Artificial Intelligence” during the transition.
    Difference
    1%
    Check dated 2026-10-26T16:52:10.000Z thumbnail image
  5. Check
    32 days ago
    Change Detected
    Summary
    The footer revision identifier changed from v3.7.1 to v3.7.2 on the ClinicalTrials.gov 403 error page.
    Difference
    0.2%
    Check dated 2026-10-19T21:56:08.000Z thumbnail image
  6. Check
    39 days ago
    Change Detected
    Summary
    The footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-13T04:25:20.000Z thumbnail image
  7. Check
    53 days ago
    Change Detected
    Summary
    The study page now shows a 403 Forbidden message, replacing the usual content, and the Home link appears to be removed, indicating restricted access to the page.
    Difference
    0.5%
    Check dated 2026-09-28T22:38:17.000Z thumbnail image

Stay in the know with updates to ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ASG-22CE Dose Escalation in Nectin-4+ Tumors Clinical Trial page.